James Richard Porter Sells 9,543 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter sold 9,543 shares of Nuvalent stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $97.16, for a total value of $927,197.88. Following the completion of the sale, the chief executive officer owned 278,629 shares of the company’s stock, valued at $27,071,593.64. The trade was a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

James Richard Porter also recently made the following trade(s):

• On Monday, January 5th, James Richard Porter sold 17,890 shares of Nuvalent stock. The stock was sold at an average price of $97.32, for a total transaction of $1,741,054.80.
• On Thursday, October 16th, James Richard Porter sold 27,000 shares of Nuvalent stock. The stock was sold at an average price of $90.63, for a total value of $2,447,010.00.

Nuvalent Stock Down 3.9%

NASDAQ:NUVL opened at $102.67 on Friday. The stock’s fifty day moving average is $102.73 and its two-hundred day moving average is $89.01. The stock has a market capitalization of $7.47 billion, a price-to-earnings ratio of -19.30 and a beta of 1.32. Nuvalent, Inc. has a 52 week low of $55.53 and a 52 week high of $112.88.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same period in the previous year, the business posted ($1.28) EPS. On average, sell-side analysts expect that Nuvalent, Inc. will post -3.86 EPS for the current fiscal year.

Nuvalent News Roundup

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: Analysts remain constructive — several firms have recently initiated/raised coverage and price targets (Cantor Fitzgerald, Leerink, Baird, Goldman Sachs, Truist among others), leaving a consensus target near $138 that supports longer-term upside. MarketBeat Nuvalent Coverage
• Neutral Sentiment: Company fundamentals reminder — Nuvalent is clinical-stage (lead assets NVL‑520, NVL‑655) and reported an EPS miss on Oct. 30 (($1.70) vs. ($1.39) expected); pipeline readouts and clinical data remain the key medium-term catalysts/risks. Earnings / Profile
• Neutral Sentiment: Institutional ownership is very high (~97%), and some small funds added modest positions recently — this reduces free-float liquidity but can amplify moves when insiders trade. Institutional Activity
• Negative Sentiment: Concentrated insider selling: CEO James R. Porter sold large blocks (17,890 shares on Jan. 5 and 9,543 shares on Jan. 6 at ~ $97 / share), a material reduction in his position that likely weighs on sentiment. SEC Filing – CEO Sales
• Negative Sentiment: CFO Alexandra Balcom and other insiders (director Christopher D. Turner, Deborah A. Miller, Henry E. Pelish) also sold multiple tranches on Jan. 5–6 (several thousand shares each), collectively trimming insider stakes and adding selling pressure. SEC Filing – CFO Sales SEC Filing – Turner SEC Filing – Miller SEC Filing – Pelish

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Nuvalent by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,605,007 shares of the company’s stock valued at $398,241,000 after acquiring an additional 80,883 shares during the period. Wellington Management Group LLP raised its position in shares of Nuvalent by 46.0% during the 3rd quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after buying an additional 724,491 shares during the period. State Street Corp boosted its stake in shares of Nuvalent by 4.2% in the second quarter. State Street Corp now owns 1,490,279 shares of the company’s stock valued at $113,708,000 after purchasing an additional 59,620 shares during the period. Commodore Capital LP boosted its position in shares of Nuvalent by 1.8% during the 3rd quarter. Commodore Capital LP now owns 1,400,000 shares of the company’s stock worth $121,072,000 after acquiring an additional 25,000 shares in the last quarter. Finally, RA Capital Management L.P. acquired a new stake in shares of Nuvalent during the third quarter worth about $107,794,000. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Analyst Ratings Changes

NUVL has been the subject of several recent analyst reports. JPMorgan Chase & Co. decreased their price target on Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. The Goldman Sachs Group boosted their price target on shares of Nuvalent from $120.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Cantor Fitzgerald initiated coverage on shares of Nuvalent in a report on Wednesday, October 15th. They issued an “overweight” rating and a $135.00 price objective for the company. UBS Group reiterated a “buy” rating on shares of Nuvalent in a report on Wednesday, December 17th. Finally, Wedbush reiterated an “outperform” rating and set a $125.00 price target (up from $120.00) on shares of Nuvalent in a report on Monday, November 17th. Fifteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $138.33.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.